All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Sandra Starnes, MD
Inderpal Sarkaria, MD

Presentations

1. Endoscopic Therapy for Early-Stage Esophageal Cancer
   Robert Van Haren, MD, MSPH
    
2. Optimal Treatment for Esophageal Adenocarcinoma: CROSS
   Monisha Sudarshan, MD MPH
   Disclosure(s): Ethicon Johnson & Johnson: Advisory Board (Terminated, June 3, 2024)
    
3. Optimal Treatment for Esophageal Adenocarcinoma: FLOT
   Jonathan Cools-Lartigue, MD, PhD
    
4. Panel Discussion
    
5. Surveillance Versus Resection Following Induction Therapy for Esophageal Cancer
   Biniam Kidane, MD MSc FRCSC
   Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Advisory Board (Ongoing), Unrestricted Educational grant (Ongoing); Merck: Advisory Board (Terminated, January 1, 2023), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 1, 2023); Olympus: Consultant (Ongoing); Roche: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
    
6. Emerging Biomarkers in Esophageal Cancer (MSI/MMR, HER2, PDL) and Implications For Treatment
   Daniela Molena, MD
   Disclosure(s): Boehringer: Consultant (Terminated, February 21, 2024)
    
7. Panel Discussion
    
8. Esophagectomy vs. Gastrectomy for Gastroesophageal Junction Tumors
   Stephanie G. Worrell, MD
   Disclosure(s): Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
    
9. Open Esophagectomy: Tips and Techniques
   Richard J. Battafarano, MD PhD
    
10. RAMIE Tips and Tricks: Is RAMIE the Preferred Approach? Update on Trials
    Lana Schumacher, MD, MS, FACS
    Disclosure(s): Medtronic: Consultant (Ongoing); AstraZeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); DaVinci Intuitive Surgical: Consultant (Ongoing)
     
11. Panel Discussion
     
12. Post-Esophagectomy Diet Management: Early Esophagram and Diet Advancement
    Luis F. Tapias, MD
    Disclosure(s): AstraZeneca: Advisory Board (Terminated, January 31, 2024); Intuitive Surgical: Consultant (Terminated, December 31, 2023)
     
13. Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: Three-Year National Perspective
    Sara Sakowitz, MS, MPH